

Intrasense presents its innovations at the European Congress of Radiology (ECR) 2024

Montpellier, France, February 26, 2024 at 5:45 pm CET

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian[®], announces its participation at the ECR from February 28 to March 3, in Vienna (Austria).

A must-attend trade show for the medical profession

Every year, the ECR attracts over 10,000 European and international radiology professionals. A major medical imaging trade show, this year's ECR will explore the latest technological and scientific advances in "Next Generation Radiology".

This first participation in ECR as an exhibitor alongside Guerbet represents a major opportunity for Intrasense to position itself in new growth markets such as Germany and Italy, offering an ideal framework for strengthening partnerships and exploring new business opportunities.

As a French expert in medical imaging, Intrasense will be presenting the latest advances in medical imaging from its Myrian[®] 2.12 solution. Designed to assist radiologists in their daily practice, this new version natively integrates artificial intelligence with innovative functionalities, notably the AI dedicated to the prostate developed by Guerbet and an AI dedicated to the analysis of lung lesions. This version is scheduled for regulatory approval and commercial launch in 2024, marking a new stage in the development of the Group's medical imaging solutions.

Participating alongside leader Guerbet

Intrasense will be present on the stand of Guerbet, its majority shareholder, demonstrating the close collaboration between the two medical imaging players. Intrasense will have a corner dedicated to its solutions, where its sales teams will present and demonstrate the latest AI innovations in the Myrian[®] solution.

Guerbet will host an exclusive symposium on artificial intelligence applied to oncology imaging on March 1, from 12:30 to 1:30 pm. The results of the Grand PI-CAI Challenge rewarding the best players in prostate cancer detection, won by Guerbet thanks to its AI algorithm and integrated into Myrian[®], will be presented.

The ECR also provides a platform for meetings. Intrasense and Guerbet will organize an event dedicated to their partners to present the perspectives offered by their collaboration in the service of excellence in oncology imaging. Hosted by François Nicolas, Senior Vice President Research, Development and Innovation and Chief Digital Officer of the Guerbet Group, and Nicolas Reymond, CEO of Intrasense, the event will also include demonstrations of innovative solutions resulting from their complementary technological expertise.

"Intrasense remains resolutely committed to a growth strategy. Our participation in the world medical imaging congresses, alongside our new reference shareholder Guerbet, testifies to our determination to offer our solutions in our key markets in Europe, and to conquer new geographies" says **Nicolas Reymond, Intrasense CEO.**

About Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing a new platform dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Intrasense

Salomé Sylvestre

Communication officer

Phone : +334 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean

Financial Communication
and investor relations

Phone : +331 44 71 20 40

intrasense@newcap.eu